SUPN— SUPERNUS PHARMACEUTICALS, INC.

MaterialsPharmaceuticals$2.7B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	—	—	—	—
Total revenues	$719.0M+8.6%	$661.8M+8.9%	$607.5M-8.9%	$667.2M
Cost of revenues	$74.6M-4.3%	$77.9M-7.0%	$83.8M-3.9%	$87.2M
Research and development	$106.2M-2.4%	$108.8M+18.8%	$91.6M+22.9%	$74.6M
Selling, general and administrative	$485.6M+51.0%	$321.6M-4.4%	$336.4M-10.8%	$377.2M
Amortization of intangible assets	$89.5M+14.7%	$78.0M-5.4%	$82.4M-0.3%	$82.6M
Intangible asset impairment charges	$0	$0-100.0%	$20.2M	$0
Contingent consideration loss (gain)	$25.4M+516.0%	-$6.1M-302.8%	-$1.5M-197.5%	-$510K
Total costs and expenses	$781.2M+34.7%	$580.2M-5.3%	$612.8M-1.3%	$621.1M
Operating earnings (loss)	-$62.3M-176.3%	$81.7M+1649.9%	-$5.3M-111.4%	$46.1M
Other income (expense)	—	—	—	—
Interest and other income, net	$13.3M-18.2%	$16.2M+55.0%	$10.5M-51.8%	$21.7M
Interest expense	$0	$0+100.0%	-$2.4M+65.8%	-$7.1M
Total other income (expense), net	$13.3M-18.2%	$16.2M+101.6%	$8.0M-45.0%	$14.6M
Earnings (loss) before income taxes	-$49.0M-150.1%	$97.9M+3434.5%	$2.8M-95.4%	$60.7M
Income tax expense (benefit)	-$10.5M-143.7%	$24.0M+1552.1%	$1.5M+4440.6%	$32K
Net earnings (loss)	-$38.5M-152.2%	$73.9M+5512.8%	$1.3M-97.8%	$60.7M
Basic (in dollars per share)	-$680.00-150.7%	$1340.00+6600.0%	$20.00-98.2%	$1130.00
Diluted (in dollars per share)	-$680.00-151.5%	$1320.00+6500.0%	$20.00-98.1%	$1040.00
Basic (in shares)	56.45B+2.5%	55.10B+1.0%	54.54B+1.6%	53.67B
Diluted (in shares)	56.45B+0.9%	55.96B+0.8%	55.51B-10.0%	61.68B
Net product sales
Collaboration revenue (ZURZUVAE)
Royalty, licensing, and other revenues

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.